Research Studies
Back to Results
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)
Details
Age
Adult
Type of Study
Treatment
Locations
Memorial Hospital Central
Memorial Hospital North
Pikes Peak Regional Hospital
Principal Investigator
Robert Hoyer
Study ID
Protocol Number: 19-6513
More information available at ClinicalTrials.gov: NCT04456699
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers